This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Alkermes' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Alkermes plc (ALKS)

Morgan Stanley Global Healthcare Conference Transcript

September 11, 2012 10:55 AM ET

Executives

Richard Pops - Chairman and CEO

Rebecca Peterson - Investor Relations

Analysts

David Friedman - Morgan Stanley

Presentation

David Friedman - Morgan Stanley

All right. So, as all of you know, since you’re in the room, the next company is Alkermes. I just need to mention that we need to refer you to any disclaimers at morganstanley.com/researchdisclosures. And it’s my pleasure to welcome Richard Pops, who is the Chairman and CEO; and also Rebecca Peterson, who runs Investor Relations.

And Richard has been CEO of the company since he joined over 20 years ago and he has led the recent successful merger with Elan Drug Technologies which closed in May of last year, and it’s a great opportunity to have you with us today. So thanks for joining. I thought that I turn it over to you to provide some brief opening remarks and then we’ll go into Q&A.

Richard Pops

Perfect. Thanks everybody. Thanks for having us. So actually that, the transaction with Elan closed September 16th of last year. So we were just -- this is the one year anniversary of what would turned out to be a merger that made a lot of sense and it made sense looking at it from prospectively and I think, now with one year under our belt, its performing exactly the way we would have hoped, if it could.

So 33,000 feet, what we’re so excited about at this moment for this company is this combination of the financial here and now with the exclusive potential of the pipeline and not a notional pipeline, not an early pipeline, but a late pipeline.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.87 -116.81 -0.68%
S&P 500 1,982.77 -11.52 -0.58%
NASDAQ 4,508.6880 -19.0010 -0.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs